Bristol-Myers, Novartis Win FDA Label Expansions for Cancer Medications

Seekingalpha2022-05-31

Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) have obtained the U.S. regulatory approval to sell their cancer medications, Opdivo and Kymriah, for additional indications in esophageal cancer...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

SSVC
2022-05-31
SSVC
K
bshian
2022-05-31
bshian
ok
AlfonsoDex
2022-05-31
AlfonsoDex
Ok
jannn
2022-05-31
jannn
[smile]
GeorgeOr
2022-05-31
GeorgeOr
Please like
PCK
2022-05-31
PCK
👍

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2239524801?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-31 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2239524801","market":"us","top_or_hot":-1,"title":"Bristol-Myers, Novartis Win FDA Label Expansions for Cancer Medications","media":"Seekingalpha","content":"<div>\n<p>Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) have obtained the U.S. regulatory approval to sell their cancer medications, Opdivo and Kymriah, for additional indications in esophageal cancer...</p>\n\n<a href=\"https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers, Novartis Win FDA Label Expansions for Cancer Medications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers, Novartis Win FDA Label Expansions for Cancer Medications\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-31 07:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) have obtained the U.S. regulatory approval to sell their cancer medications, Opdivo and Kymriah, for additional indications in esophageal cancer...</p>\n\n<a href=\"https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications","article_id":"2239524801","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2239524801","pubTimestamp":1653952686,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) have obtained the U.S. regulatory approval t","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝","NVS":"诺华"},"translate_title":"百时美和诺华赢得FDA癌症药物标签扩展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"NVS":0.9},"content_text":"Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) have obtained the U.S. regulatory approval to sell their cancer medications, Opdivo and Kymriah, for additional indications in esophageal cancer and blood cancer, respectively.Accordingly, Opdivo, known as nivolumab in generic terms, is allowed as a first-line option to treat adults with unresectable esophageal squamous cell carcinoma regardless of the PD-L1 expression in tumors.The FDA has greenlighted two Opdivo-containing regimens for the indication: Opdivo with fluoropyrimidine and platinum-containing chemotherapy as well as Opdivo plus Yervoy.The approval was based on data from a late-stage trial called CheckMate -648 in which Opdivo in combination with Chemotherapy and Opdivo plus Yervoy outperformed chemotherapy alone.Currently, Opdivo-based regimens are allowed in five indications in upper gastroesophageal cancers.Meanwhile, Novartis (NVS) said that the FDA granted accelerated approval for Kymriah for adults with relapsed or refractory follicular lymphoma as a third-line option following at least two systemic treatments.With the latest regulatory nod, Kymriah (tisagenlecleucel) is approved for three blood cancer types in the U.S. The CAR-T cell therapy generated $587M net sales in 2021 with ~24% YoY growth.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9027937198,"gmtCreate":1653957984514,"gmtModify":1676535369009,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3574906731000207","idStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027937198","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9027026346,"gmtCreate":1653954351085,"gmtModify":1676535367008,"author":{"id":"3576896763784132","authorId":"3576896763784132","name":"bshian","avatar":"https://static.tigerbbs.com/ea8813b91ae8bba6f3905bb49e6986be","vip":1,"crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"3576896763784132","idStr":"3576896763784132"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027026346","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9027066229,"gmtCreate":1653953927061,"gmtModify":1676535366792,"author":{"id":"4098943201642940","authorId":"4098943201642940","name":"AlfonsoDex","avatar":"https://community-static.tradeup.com/news/3c3dacba85c0b4dfd791bb1be953f1ec","vip":1,"crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"4098943201642940","idStr":"4098943201642940"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027066229","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9027085076,"gmtCreate":1653953555095,"gmtModify":1676535366426,"author":{"id":"3580090055250591","authorId":"3580090055250591","name":"jannn","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3580090055250591","idStr":"3580090055250591"},"htmlText":"[smile]&nbsp;","listText":"[smile]&nbsp;","text":"[smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027085076","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9027086743,"gmtCreate":1653953518482,"gmtModify":1676535366403,"author":{"id":"3570922030489337","authorId":"3570922030489337","name":"GeorgeOr","avatar":"https://static.tigerbbs.com/590cc7dd964e0cf6e057302728902b7b","vip":1,"crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3570922030489337","idStr":"3570922030489337"},"htmlText":"Please like&nbsp;","listText":"Please like&nbsp;","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027086743","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9027086583,"gmtCreate":1653953504542,"gmtModify":1676535366395,"author":{"id":"3568080589577956","authorId":"3568080589577956","name":"PCK","avatar":"https://static.tigerbbs.com/31fca8dc8270fe22c49e0f5ad8bfdc4c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3568080589577956","idStr":"3568080589577956"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9027086583","repostId":2239524801,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":92,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2239524801"}